Moreover, recently proven CSC hypothesis in various cancers including PDAC ascertains that there are specific alterations, including overexpression of CD133, Sox2, CXCR4 and Pancreatic differentiation 2 (PD2) in a minor subpopulation of cancer cells, which are responsible for chemotherapeutic resistance and tumor recurrence [7–9]. This evidence concerns the gene SOX2 and cancer.